PremiumRatingsAkoya Biosciences: Hold Rating Amid Revenue Decline and Merger Uncertainties Quanterix price target lowered to $15 from $20 at Canaccord Akoya Biosciences reports Q4 EPS (17c), consensus (16c) PremiumThe FlyAkoya Biosciences unveils strategic product roadmap Akoya Biosciences selects Argonaut Manufacturing as IVD manufacturing partner Quanterix price target lowered to $11 from $15 at TD Cowen PremiumThe FlyMorgan Stanley, Comerica upgraded: Wall Street’s top analyst calls Akoya Biosciences downgraded to Hold from Buy at Craig-Hallum Akoya Biosciences price target lowered to $3.50 from $6 at Canaccord 
